Breaking
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect ProgramEli Lilly's Legal Victory Over Noom's GLP-1 ClaimsBBSW AI Solution Event: Daily Roundup
Friday, June 19, 2026
🇺🇸 FDA

Schizophrenia News

🇺🇸 FDA

FDA breaking news and regulatory updates for BD, investors, and analysts

Showing 1–3 of 3 articles

Critical impact NewsApr 28, 2026

FDA Approves Johnson & Johnson's CAPLYTA (Lumateperone) sNDA for Schizophrenia Relapse Prevention

FDA · 2 min

Dr. Natalie Hughes
Critical impact NewsApr 24, 2026

ACRP 2026: Immunology Updates and Clinical Research Trends

immunology · 12 min

Dr. Sarah Mitchell
High impact NewsApr 23, 2026

Neurosterix NTX-253 Phase 1 Schizophrenia Trial On Track for Q2 2026 Completion

2 min

Dr. Laura Bennett

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.